A detailed history of Two Sigma Investments, LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 130,095 shares of RNA stock, worth $5.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
130,095
Previous 225,746 42.37%
Holding current value
$5.49 Million
Previous $9.22 Million 35.2%
% of portfolio
0.01%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$37.21 - $48.14 $3.56 Million - $4.6 Million
-95,651 Reduced 42.37%
130,095 $5.98 Million
Q2 2024

Aug 14, 2024

SELL
$22.73 - $40.85 $489,922 - $880,480
-21,554 Reduced 8.72%
225,746 $9.22 Million
Q1 2024

May 15, 2024

SELL
$9.16 - $25.52 $3.85 Million - $10.7 Million
-420,233 Reduced 62.95%
247,300 $6.31 Million
Q4 2023

Feb 14, 2024

BUY
$4.87 - $9.37 $507,410 - $976,269
104,191 Added 18.5%
667,533 $6.04 Million
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $305,682 - $550,713
48,521 Added 9.42%
563,342 $3.59 Million
Q2 2023

Aug 14, 2023

BUY
$10.62 - $17.34 $1.98 Million - $3.23 Million
186,333 Added 56.72%
514,821 $5.71 Million
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $3.4 Million - $5.68 Million
221,588 Added 207.29%
328,488 $5.04 Million
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $870,099 - $1.96 Million
86,491 Added 423.79%
106,900 $2.37 Million
Q3 2022

Nov 14, 2022

BUY
$15.46 - $23.43 $315,523 - $478,182
20,409 New
20,409 $333,000
Q4 2021

Feb 14, 2022

SELL
$20.4 - $28.66 $283,560 - $398,374
-13,900 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $252,424 - $350,419
13,900 New
13,900 $342,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.2B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.